SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

04 Aug 2022 Evaluate
The June 2022 quarter revenue stood at Rs. 1199.36 millions, up 8.09% as compared to Rs. 1109.56 millions during the corresponding quarter last year.The company has announced a 46.55% increase in its profits to Rs . 98.00  millions for the  quarter ended June 2022 compared to Rs. 66.87 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 166.50 millions compared to 130.74 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1199.36 1109.56 8.09 1199.36 1109.56 8.09 4659.30 4276.02 8.96
Other Income 28.58 6.89 314.80 28.58 6.89 314.80 67.06 30.94 116.74
PBIDT 166.50 130.74 27.35 166.50 130.74 27.35 596.01 577.86 3.14
Interest 3.50 4.82 -27.39 3.50 4.82 -27.39 14.17 12.90 9.84
PBDT 163.00 125.92 29.45 163.00 125.92 29.45 581.84 241.45 140.98
Depreciation 27.56 30.25 -8.89 27.56 30.25 -8.89 121.47 129.65 -6.31
PBT 135.44 95.67 41.57 135.44 95.67 41.57 460.37 111.80 311.78
TAX 37.44 28.80 30.00 37.44 28.80 30.00 74.76 61.70 21.17
Deferred Tax 0.96 -0.07 -1471.43 0.96 -0.07 -1471.43 -26.57 13.28 -300.08
PAT 98.00 66.87 46.55 98.00 66.87 46.55 385.61 50.10 669.68
Equity 108.97 91.04 19.69 108.97 91.04 19.69 108.97 64.11 69.97
PBIDTM(%) 13.88 11.78 17.82 13.88 11.78 17.82 12.79 13.51 -5.34

Windlas Biotech Share Price

865.40 -6.35 (-0.73%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×